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ABSTRACT
Introduction: Atopic dermatitis (AD) is a com-
mon chronic inflammatory skin disease; it
requires long-term treatments focused on
symptomatic relief. Current first-line treatments
include moisturizers and topical corticosteroids.
Recently, topical antioxidants have been added
to moisturizer formulations to alleviate mild-to-
moderate AD. The aim of this review was to
evaluate the efficacy and tolerability of furfuryl
palmitate, a new antioxidant molecule, and
furfuryl derivatives.
Methods: A PubMed/Google Scholar search was
conducted using the term ‘‘furfuryl palmitate’’
(and its derivatives, including AR-GG27)
combined with ‘‘skin,’’ ‘‘atopic dermatitis,’’ and
‘‘atopic eczema.’’ Existing trials including adult
and pediatric patients with AD and related skin
disorders were evaluated. The treatment indi-
cation(s), number of subjects, treatment proto-
cols, results, and side effects were recorded.
Results: Effective treatments with furfuryl
palmitate and furfuryl derivatives have been
reported for the following conditions: atopic,
seborrheic, irritative, and allergic contact der-
matitis, eczema, xerosis, and cutaneous inflam-
matory pathologies. All the products tested
showed a good tolerability profile.
Conclusion: Studies performed up to now
showed that furfuryl derivatives can effica-
ciously contrast signs and symptoms of mild-to-
moderate AD, erythema, and widespread diffuse
cutaneous pathologies in both adult and pedi-
atric patients, representing a real alternative to
steroids and a valid aid in the treatment of skin
disorders, with no side effects and without
requiring precautions in use.
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summary available for this article.
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PLAIN LANGUAGE SUMMARY
Atopic dermatitis (AD), also called eczema, is a
common skin disease. Its main symptoms are
redness and itching of the skin, but symptoms
can vary from person to person; it also presents
features of asthma and/or hay fever. It tends to
flare periodically and clear up for the rest of the
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time. It is a disease more common in childhood,
but may persist in adolescence and adulthood.
There is no cure for this disease, but it
requires long-term treatments to relieve itching
and prevent new outbreaks. First-line treatment
includes substances called skin moisturizers
(that help prevent skin dryness) and corticos-
teroids (drugs that can lessen redness and itch-
ing). Recently, substances called antioxidants
have been added to moisturizer formulations to
alleviate AD symptoms. Antioxidants can pro-
tect the skin from damage caused by harmful
molecules called free radicals.
Our research aimed to evaluate the efficacy
and safety of using furfuryl palmitate, a new
antioxidant, and furfuryl derivatives added to
moisturizer formulations. A literature search
was conducted, and existing research works
including adult and pediatric patients with AD
and related skin disorders were evaluated.
What has been seen up to now is that fur-
furyl palmitate and its derivatives can effica-
ciously contrast symptoms of mild and
moderate AD, erythema, and widespread diffuse
cutaneous disturbances in both adult and
pediatric patients. Thus, this treatment repre-
sents a valid aid in the treatment of skin disor-
ders, with no side effects and without requiring
precautions for use.
INTRODUCTION
Atopic dermatitis, also referred as ‘‘atopic
eczema’’ or ‘‘eczema,’’ is a common, non-con-
tagious, chronically relapsing and inflammatory
skin disease [1–4], usually associated with
asthma and inhalant allergies [5]. It usually
appears in childhood, but with growth most
children move to a condition that no longer
requires medical care; adults make up only
about one-third of all cases. A hereditary com-
ponent of the disease is known,but a crucial role
in disease expression can be attributed to the
environment [6–9].
The clinical features leading to a diagnosis of
AD are variable, but the hallmark of atopic
dermatitis is extremely itchy and dry skin
[10–13], resulting in impaired skin barrier
function, causing cutaneous inflammation and
increased transepidermal water loss (TEWL).
Also, the lack of intercellular lipids in the stra-
tum corneum and inadequate ratios among
compounds (cholesterol, essential fatty acids,
ceramides), typical of AD patients, enhance
TEWL, leading to epidermal microfissuring,
facilitating easier allergen penetration [14, 15].
Atopic dermatitis, being a complex and
multifactorial disease, can be treated by differ-
ent physicians according to different therapies
and approaches. However, all clinical modifi-
cations have to be considered as one condition
and, requiring AD lifelong or long-term per-
spective treatments, special attention must be
given to safety aspects.
Several guidelines have been published [16]
to suggest a proper clinical approach to manage
AD, but the goal of any treatment is to gain a
state in which no or only minor symptoms
occur and drug treatments are not much nee-
ded, with the disease rarely showing acute or
intense exacerbations. No treatments can heal
the disease, but treatments basically focus on
symptom relief.
All themanagement guidelines review topical
therapy for AD [17–20]; current first-line treat-
ment includes moisturizers and topical corti-
costeroids. According to the European Academy
of Allergy and Clinical Immunology and the
American Academy of Allergy, Asthma and
Immunology [11], the regular use ofmoisturizers
represents the mainstay of the general manage-
ment of AD and of maintenance of remission
from flares [10]. They relieve the severe dryness
of the atopic skin and the accompanying symp-
toms, such as intense pruritus and inflamma-
tion, improving the barrier function and
decreasing the TEWL [21]. Their constant use
could be sufficient to control mild eczema and
should also form part of the treatment regimen
formore severe forms, being also able to decrease
the use of topical steroids [22–25].
Moisturizers ideally perform all the following
functions: improve skin barrier functions by
delivering lipids and water to the stratum cor-
neum [26] (restoring barrier function and thus
also ameliorating antimicrobial defense);
maintain skin integrity and appearance; reduce
TEWL; facilitate barrier repair by encouraging
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the natural restorative process [27, 28]. They
can be formulated in a variety of delivery sys-
tems and have different compositions and
properties to enhance efficacy; the most effica-
cious moisturizers contain both occlusive and
humectant ingredients [18, 21, 26, 29].
Moisturizers are considered very safe, but
adverse skin reactions are not uncommon, also
considering that atopics are particularly at risk
for adverse skin reactions because of their
impaired barrier function, whereas systemic
side effects are extremely rare [30, 31].
Recently, new antiinflammatory agents have
been added into the moisturizer formulations to
alleviate mild to moderate AD. The term PED
(prescription emollient devices) has been intro-
duced to identify this new class of topical agents
designed to target the specific defects in skin
barrier function observed in AD, and they con-
tain several components including antiinflam-
matory agents, emollients or humectants. PEDs
are also knows as prescription barrier repair
creams (BRCs) [18, 28, 32, 33]. They are
approved as 510(k) medical devices based on the
assertion that they serve a structural role in skin
barrier function and do not exert their effects by
any chemical actions. The moisturizers qualify
as devices because they can change the water
content of the skin, demonstrated by measuring
the TEWL. According to this approval route,
safety, not efficacy, is of primary concern.
These compounds represent the answer to
the awareness of the primary role of the stratum
corneum in the pathogenesis of AD and of the
need not only to treat the inflammation but
also to restore the barrier, delivering stratum
corneum-specific lipids to help correct the epi-
dermal barrier dysfunction [34].
PEDs may provide additional barrier repair
and control xerosis without topical corticos-
teroid treatment and include preparations hav-
ing distinct ratios of lipids that mimic
endogenous compositions.
PEDs may contain an antioxidant agent,
such as furfuryl palmitate or furfuryl deriva-
tives. Oxidative stress and altered antioxidant
defenses are involved in the pathophysiology of
acute exacerbation of AD, and AD patients are
more prone to report damages caused by reac-
tive oxygen species (ROS) or oxidants. Thus, it is
possible that antioxidants may be beneficial in
the treatment of AD, i.e., that suppressing the
oxidative stress may be a potentially useful
strategy for the treatment of AD [1, 35–39].
Furfuryl palmitate is an ester obtained when
furfuryl alcohol reacts with palmitic acid, and it
has remarkable singlet oxygen-quenching
properties, 1O2. This is a radical with no ionic
charge and relatively low reactivity, which
facilitates its spread through the dermis and
into the cells, where it can damage cytoplasmic
structures and nuclear material. Besides being
one of the prime causes of skin aging, 1O2 plays
a role in the genesis of symptomatic topical
disorders such as irritant and allergic contact
dermatitis, seborrheic dermatitis, inflamma-
tion, psoriasis and sun erythema [30, 40].
1O2 is formed from atmospheric O2 by pho-
tochemical activation, and the process has
intensified in recent years following the thin-
ning of the ozone layer and the reduction in its
protection against UV radiation. Production of
1O2 from O2 is effectively inhibited by the pres-
ence of furfuryl alcohol, as widely demonstrated
by experimental data [41]. Thanks to the pres-
ence of a conjugated diene, furfuryl alcohol and
its derivatives can interact with PO2 by either
conversion to oxygen in the ground state (triplet
state) or sequestering the radical through a Dies
Alder type diene dienophile addition reaction.
Esterification of the furyl ring with palmitate
enhances molecule penetration into the mem-
branes, thus facilitating skin absorption [42].
In 2008, furfuryl derivatives and their use in
the treatment of dermatologic disorders, espe-
cially when caused by free radicals, were the
objects of a US patent [43].
The first in vitro experiments for sorbityl
furfural palmitate (ARGG27) demonstrated its
antioxidant and lenitive actions [44, 45], sup-
porting the hypothesis of a positive effect of the
ARGG27 molecule on the control of AD and
other inflammatory skin diseases.
METHODS
A search using PubMed and Google Scholar was
conducted up to September 2017 using the term
‘‘furfuryl palmitate’’ (and its derivatives
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including AR-GG27) combined with ‘‘skin,’’
‘‘atopic dermatitis,’’ ‘‘atopic eczema,’’ ‘‘dermati-
tis’’ and ‘‘eczema.’’ The search results were
reviewed for clinical trials, case reports and case
series examining the usage and efficacy of fur-
furyl palmitate to treat dermatologic condi-
tions. The following information was recorded
from these publications: the dermatologic con-
dition being studied, test agents, number of
subjects, treatment protocol, results and safety
profile.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Six papers on furfuryl palmitate and its deriva-
tive therapies (meeting the following criteria:
being a clinical study; having furfuryl palmitate
and its derivatives as one of the experimental
agents; describing a dermatologic application
for furfuryl palmitate and its derivatives) were
obtained and reviewed, including adult and
pediatric patients with AD and related skin
disorders.
The studies are outlined in Table 1
[37, 42, 46–49].
In the clinical study by Tripodi et al. [49], the
efficacy and tolerability of furfuryl palmitate
were evaluated, and the main results are shown
in Table 1.
The quality and scientific validity of the
study have been challenged, based on the fol-
lowing issues.
Concerning the study product, the percent-
age of furfuryl palmitate was not specified, thus
potentially invalidating the study and in any
case confounding the outcome, and a proper
placebo or a pure emollient alone (as control)
was missing. Concerning the study methodol-
ogy, it seemed that only a comparison within
groups was presented, whereas a comparison
between groups was missing; furthermore, the
statistical power calculation was at minimum
- 80%, invalidating the reliability of conclu-
sions. No superiority or non-inferiority design
was clarified, and only results for the per
protocol populations were reported (this could
also be the reason for the discrepancy between
the table and figure reporting mean SCORAD
index scores). The sample size (relatively small)
was not based on differences from baseline, and
a possible bias in statistics could also be attrib-
uted to the difference in food allergy in the
groups (respectively 28% and 39% in group A
and B). Concerning patient selection, eligibility
criteria were not completely clarified, no mini-
mal/maximal severity of disease score was
mentioned for inclusion, and the SCORAD
index was not homogeneous between groups,
being 25.6 (mean score, corresponding to
‘‘mild,’’ up to 25) in the basic emollient cream
group, group A, and 28.1 (mean score, corre-
sponding to ‘‘moderate,’’ between 25 and 50) in
the furfuryl palmitate cream group, group B.
The analysis seemed not to have considered this
difference, and the standard deviation was high
(respectively 10.1 and 10.6 in group A and B),
increasing the doubts regarding patient
selection.
CONCLUSIONS
Moisturizers traditionally have a key role in
improving and maintaining the skin barrier
function and reducing skin susceptibility to
irritants; they represent the standard care for
AD therapy, useful for both prevention and
maintenance therapy, and it has been shown
that their regular use has a short- and long-term
steroid-sparing effect in mild-to-moderate AD.
Over time, the traditional therapy based on
moisturizers has been enriched and improved
by topical agents for physiologic lipid base
barrier repair. They focus on physiologic lipid
replacement therapy, particularly ceramides,
being able to restore the normal balance of the
epidermal barrier.
Several studies demonstrated that these
agents are safe and effective in treating AD, as
either monotherapy or adjuvant treatment,
showing comparable efficacy, in terms of
improving symptoms and timing to resolution
compared with traditional agents [28, 50].
Today, considering the new research per-
formed on the role of oxidative stress in AD,
342 Dermatol Ther (Heidelb) (2018) 8:339–347
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products enriched in antioxidants, such as fur-
furyl derivatives, can represent a valid aid in the
treatment of a range of skin disorders, such as
atopic and seborrheic dermatitis, with no side
effects or requirement of precautions in use.
Even if the preliminary data shown should
be confirmed in larger trials considering both
pediatric and adult patients, studies performed
up to now have shown that furfuryl derivatives
are able to efficaciously contrast the signs and
symptoms of mild-to-moderate AD and ery-
thema and also widespread diffuse cutaneous
pathologies, such as irritative, seborrheic and
allergic contact dermatitis, in both adult and
pediatric patients [37, 42, 46–48]. The only
paper published up to now not agreeing with
what is outlined here is biased by several issues,
as discussed above, whereas all other clinical
investigations carried out not only did not
highlight any negative aspects, but instead
confirmed several positive outcomes, showing a
clear superiority of verum with respect to
placebo.
The products containing these compounds
can constitute a valuable alternative to topical
corticosteroids in mild-medium severity skin
disorders, especially when preferring to avoid a
pharmacologic agent, such as in pediatric
patients, intolerant subjects or atopic patients.
In addition, they can also act in synergy with
other topical or systemic treatments, as well as
pharmacologic, to promote faster recovery of
the normal skin condition, reducing inflam-
mation and restoring the skin barrier.
Thus, in patients with mild or moderate AD,
these products represent a real alternative to
steroids, which instead constitute an important
health risk.
All the products tested showed, in addition, a
good tolerability profile, thus promoting com-
pliance by both the patient and caregiver. This
is of main importance, because the choice of
therapy can be primarily considered as depen-
dent on the patient’s preferences and also the
ideal moisturizing agent should be safe, effec-
tive, inexpensive.
Despite the positive results outlined above in
the confirmatory studies, research with bigger
sample sizes is advisable to confirm and
emphasize the results already achieved.
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